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Abstract 
Intraductal papillary neoplasm of bile duct (IPNB) was described as a preinvasive neoplastic lesion 
of the biliary tract in the 2010 WHO classification. Although a number of studies have since been 
conducted on IPNBs, controversy remains, particularly regarding the standardization of its definition. 
Meetings by Japanese and Korean expert pathologists were held twice to resolve the pathological 
diagnostic aspects of IPNB. Through round-table discussions and histological reviews, we reached to 
the common understandings that IPNBs diagnosed according to the criteria of WHO 2010 are 
characterized by intraductal predominant papillary or villous biliary neoplasms covering delicate 
fibrovascular stalks and are classified into two types pathologically. One type (type 1 IPNB) is 
histologically similar to intraductal papillary mucinous neoplasms of pancreas, and typically 
develops in the intrahepatic bile ducts, while the other (type 2 IPNB) has a more complex 
histological architecture with irregular papillary branching or with foci of solid-tubular components 
and typically involves the extrahepatic bile ducts. This report states the diagnostic pathologic 
features of IPNB proposed by WHO 2010. Since currently, the concept of IPNB is still confusing, 
the proposed diagnostic pathologic features stated here will be of use for future clinicopathological 
and molecular analyses toward consensus building of IPNB. 
 Nakanuma -4- 
Introduction 
The 2010 WHO classification states that “IPNBs (intraductal papillary neoplasms of the bile 
duct) are characterized by dilated bile ducts filled with a non-invasive papillary or villous biliary 
neoplasms covering delicate fibrovascular stalks” [1,2]. While IPNBs are a pre-invasive neoplasm, it 
is called “IPNB associated with an invasive carcinoma” when they begin invasion. However, the 
prevalent location of IPNBs is highly variable among studies (~80% of tumors located in the 
intrahepatic bile duct in some studies; ~70% in the extrahepatic bile duct in others) [3-8]. The 
reported incidence of associated invasive malignancy in IPNBs also varies between 31% and 74% 
[3-8]. The incidence of low/intermediate dysplasia and high-grade dysplasia in IPNB are also 
different among the reports. Some reported that all cases were high-grade dysplasia (carcinoma in 
situ) with or without invasion, while others reported that about 10 to 20% of IPNB are benign 
(adenoma or low/intermediate dysplasia) (9-11). These discrepant findings among previous studies 
on IPNB could be, at least partly, due to the different diagnostic criteria applied. 
Currently there is some confusion in understanding pathologic features of IPNB. One is with 
respect to the similarity to the intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. It 
has been reported that IPNBs share pathological features of IPMNs of the pancreas [1,6,12-14]. 
IPMNs are also preinvasive intraductal papillary neoplasms of the pancreas and in addition, IPNBs 
and IPMNs are known to share similar subtypes [1,6,12-14]. However, there are several reports that 
some of IPNB were similar to IPMN and the others were not, and the differences and similarities 
between IPNB and IPMN have not yet been fully clarified. Another is with respect to the difference 
between IPNB and papillary cholangiocarcinoma. Prior to WHO 2010 proposal of IPNB, 
Albores-Saavedra, et al. reported invasive and non-invasive papillary carcinomas as a distinct 
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morphological variant of extrahepatic and gallbladder cancers based on their well-differentiated 
morphology and favorable prognosis [15,16]. Although in WHO 2010 proposal, papillary carcinoma 
reported by Albores-Saavedra, et al. [15,16] was included in IPNB of the extrahepatic bile ducts and 
in intracystic papillary neoplasm (ICPN) of the gallbladder [1,2], this inclusion might have not been 
well recognized and caused some misunderstanding [15,16]. Since most cases of IPNBs reported at 
that time of WHO 2010 proposal were intrahepatic tumors, only limited data were available on 
extrahepatic IPNBs [12-14], and pathological features had not been compared between intrahepatic 
and extrahepatic papillary neoplasms at that time. Therefore, it still remains to be clarified whether 
IPNB proposed by WHO 2010 is a single disease or is composed of several heterogeneous diseases.   
Thus, it seems reasonable and timely that the pathological features of IPNB, particularly with 
respect to its similarities to IPMNs and also to its anatomical location along the biliary tract, should 
be discussed by experienced pathologists from different institutions and different countries in order 
to polish, refine and prevail the diagnostic pathologic criteria of IPNB originally proposed by WHO 
2010, which would be a cornerstone for future clinicopathological and molecular analyses of IPNB 
for building consensus on what IPNB is.  
A Japan-Korea study group on IPNBs jointly sponsored by the Japan Biliary Association and 
Korean Association of Hepato-Biliary and Pancreas Surgery was established. For clinicopathological 
analyses of IPNB cases collecting from many institutions, pathologic diagnostic criteria for IPNB are 
mandatory. For this purpose, expert pathologists of IPNB from Japan and from Korea supported by 
the Japan-Korea study group on IPNBs met in 2016 and again in 2017. This study protocol was 
approved by the institutional review board of the Dokkyo Medical University (IRB No.28059). This 
is a statement by experienced pathologists on characteristic and diagnostic pathologic features of 
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tumors currently diagnosed as IPNB and its possible subclassification.  
 
Review of the literatures regarding the histological heterogeneity of IPNBs 
   Several recent studies were reviewed with respect to the heterogeneity of intraductal biliary 
papillary neoplasms in order to understand and share the pathologic features of IPNBs by 
experienced pathologists and to obtain a better pathologic diagnostic criteria of IPNBs.  
   Nakanuma, et al. examined IPNBs arising in the intrahepatic and extrahepatic bile ducts, and 
reported that approximately one half of IPNBs showed similar histopathological features to IPMNs, 
while the other half appeared not to be similar to IPMNs [17]. IPNBs resembling pancreatic IPMNs 
typically developed in the intrahepatic bile duct, and the gastric type was the most common 
phenotype, followed by the intestinal and oncocytic types. Mucin hypersecretion was also more 
frequently observed in IPMN-like cases than in IPMN-unlike cases. Most IPMN-unlike IPNBs 
developed in the extrahepatic bile ducts, and most were histologically the intestinal or 
pancreatobiliary type, and mucin secretion was occasional. IPMN-like IPNBs often contained foci of 
low/intermediate-grade dysplasia and not infrequently showed invasion. The most of “IPMN-unlike” 
tumors showed high-grade dysplasia with a few identifiable areas of low/intermediate-grade 
dysplasia, and had invasive frequently adenocarcinomas at the time of surgical resection. Ohtsuka et 
al. also reported that mucin hypersecreting IPNBs showed striking similarities to IPMN and were 
usually in situ or minimally invasive, but IPNBs without mucin hypersecretion showed different 
phenotypes and frequent p53 and MUC1 expression from the former and were always invasive [8].  
   Zen, et al. recently proposed stringent histological criteria for “IPNBs” in order to discriminate 
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IPNBs from “papillary cholangiocarcinomas” [9]; “IPNB” was re-defined as a papillary neoplasm 
that was usually confined to the epithelium and infrequently associated with invasion and was 
regularly arranged in a high-papillary architecture along thin fibrovascular stalks with an overall 
uniform proliferation pattern throughout the tumor and typically developed in the intrahepatic or 
hilar bile ducts, while the tumors with more complex papillary structures (e.g., irregular papillary 
branching or mixed with solid–tubular growth) were termed “papillary cholangiocarcinoma” and 
were most often observed in the extrahepatic bile ducts.  
 
Common understanding the pathological features of IPNB by Japan-Korea expert pathologists  
   Two meetings by expert pathologists from different institutions and countries were organized by 
the Japan-Korea study group on IPNBs to discuss pathological aspects of IPNB based on our own 
experiences, and also by reviewing published English literatures, particularly WHO 2010 
classification [1,2] and by observing histology of selected IPNB cases. We had round-table 
discussions as well as histology reviews of IPNBs using a multiheaded microscope. The first 
meeting was held in Sendai, Japan, on 6th, August, 2016, and three Japanese (YN, NF, and TF) and 
two Korean pathologists (SMH and KTJ) participated. A total of 15 representative surgical cases of 
IPNB (9 males and 6 females with a mean age of 65 years ranging from 40 to 76 years, 9 cases of 
IPNB mainly affecting the intrahepatic bile ducts and 6 cases of IPNB mainly affecting the hilar and 
extrahepatic bile ducts) were examined with respect to four subtypes (intestinal, gastric, 
pancreatobiliary and oncocytic type), grades of dysplasia, and other histology in consideration of 
WHO 2010 classification, height, much mucin hypersecretion, considerable tubular components, and 
preinvasion and invasion. All of these cases of IPNB were diagnosed as IPNB according to the 
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criteria of WHO 2010 [1, 2]. The intraluminal or intracystic papillary neoplasm of the gallbladder 
and amuplla Vater were not included. Five cases of conventional nodular/sclerosing 
cholangiocarcinoma of hilar regions with intraductal nodular/papillary components were used as a 
control. All of these cases belonged to one medical center in Japan (Shizuoka Cancer Center, Japan), 
and a pathologist of this center (YN) selected these IPNB cases and control cases for this meeting. In 
each of these cases, more than 20 tissue sections including tumor parts and adjacent non-tumorous 
bile ducts were prepared, and routinely stained sections including H&E, mucin and collagen fiber 
stainings of representative sections were available. In addition, immunostaining of several 
representative sections for S100P, MUC1, MUC2, MUC5AC, MUC6, CDX2, CK7, CK20, CDX2, 
CD10, and p53 were also available in all cases. Concise clinical data including surgical procedures 
and imagings were also available.  
   After reviewing histologic sections and thorough discussions, we reached to share the common 
understandings related to the characteristic and diagnostic pathologic features of IPNB and its 
possible subclassification, and a rough draft on these issues was written and sent to all participants.  
Then, the second meeting was held in Seoul, Korea, on 11th and 12th, February, 2017, for further 
discussion on IPNB, focusing on validation and polishment of common understandings of the 
pathologic features of IPNB and subclassification in Sendai by recruiting three new pathologists. 
First, we generally approved the IPNB draft (the common understanding of the characteristic 
pathologic features of IPNB and subclassification). Then, we reviewed histologically 20 cases of 
IPNB of the intrahepatic and extrahepatic bile ducts under multihead microscope. In this second 
meeting, only one representative H&E section from each case was examined. Though there were 
several controversies among pathologists on diagnostic criteria of IPNB such as the mucin secretion, 
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height, and grade of dysplasia and also subclassification of IPNB, the second meeting was 
successfully finished. After then, several issues continued to be discussed by email. Eventually, the 
common understandings on the pathologic features of IPNB and its subclassification were obtained 
as follows, though actual data were not obtained through these two meetings due to unique progress 
of two meetings. 
 
A. Characteristic pathologic features of IPNB 
i) Gross findings: IPNBs that show predominant intraductal growth occur in the intrahepatic and 
extrahepatic bile ducts. The macroscopic appearance of IPNBs highly varies among cases. 
Intrahepatic IPNBs frequently shows cystic dilatation of the affected duct, while extrahepatic IPNBs 
are typically associated with cylindrical or fusiform dilatation of the affected ducts. 
ii) Histological findings and subtypes: IPNBs are characterized by intraductal papillary or villous 
biliary neoplasms covering delicate fibrovascular stalks. Some are nearly identical to pancreatic 
IPMNs microscopically, while others show different features including a complex papillary 
architecture and association with foci of solid-tubular growth. Most IPNBs arising in the intrahepatic 
bile ducts share pathologic features with IPMNs, while IPNBs in the extrahepatic bile ducts are 
microscopically less similar to IPMN. Four histological subtypes (gastric, intestinal, pancreatobiliary, 
and oncocytic types) may be observed in IPNBs, particularly IPMN-like cases. However, IPNBs 
often comprise more than one histological subtype.  
iii) Degree of dysplasia: Although most IPNBs arising in the intrahepatic bile ducts are graded as 
high-grade dysplasia based on the highest degree of cellular atypia, areas of low/intermediate-grade 
dysplasia sometimes co-exist. Actually, some intrahepatic IPNB cases are composed of 
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low/intermediate dysplasia (adenoma). In contrast, a majority of IPNBs arising in the extrahepatic 
bile ducts are typically composed of high-grade dysplasia with occasional small areas of 
low/intermediate-grade components.  
iv) Association with invasive malignancy: Unlike intrahepatic IPNBs, which are not infrequently 
non-invasive at the time of resection (~50% of cases), most extrahepatic papillary neoplasms have at 
least focal stromal invasion. The former appears to be less aggressive than the latter. Invasive 
carcinomas are mainly tubular or occasionally mucinous carcinomas, though they do not show 
papillary structures as seen in the intraluminal papillary neoplasm. 
 
B. Subclassification of IPNB and diagnostic pathologic features 
The relation between IPNB proposed by WHO 2010 and so-called papillary carcinoma or 
cholangiocarcinoma of extrahepatic bile ducts reported prior to WHO 2010 proposal was also 
discussed in these meetings. It was concluded that papillary carcinoma reported by Albores-Saavedra 
et al [15,16] and papillary cholangiocarcinoma by Zen et al [9] develop in the extrahepatic bile ducts 
and IPNBs with more similar features to IPMN typically develop in the intrahepatic bile ducts, 
though there may be histological overlaps between these two neoplasms. So, it is one of our common 
understandings that currently diagnosed IPNBs can be heterogeneous in their morphologies and 
biological activities according to its similarities to IPMN and its anatomical location along the 
biliary tree. So, while the term IPNB was used for all intraductal papillary neoplasm arising in the 
bile ducts in the WHO 2010 classification, IPNB based on it could be subclassified into two types 
(type 1 and type 2): the prototype of type 1 is “classical IPNB”, commonly in the intrahepatic bile 
duct with more or less similar features of IPMN, and that of type 2 is “so called papillary carcinoma 
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or cholangiocarcinoma” with a more complex histologic papillary architecture typically arising in 
the extrahepatic bile duct. While IPNB itself is a preinvasive biliary neoplasm of the bile duct, type 2 
IPNBs are mostly associated with invasion and type 1 IPNBs are also not infrequently associated 
with invasion at the time of surgical resection. Interestingly, invasive carcinoma areas of both types 
were mainly tubular and occasionally mucinous. The key gross and microscopic features of these 
neoplasms are summarized in Table 1. We also propose the following criteria for the pathologic 
diagnosis of the two types of IPNBs.  
 
1. Type 1 IPNB (Classical IPNB) 
i) This is principally a papillary neoplasm consisting of the lining neoplastic epithelium and delicate 
fibrovascular stalks (Figures 1A and 1B). Growth patterns vary among cases, but are relatively 
uniform and well organized in individual tumors.  
ii) Papillary stalks are generally thin, but occasional foci of edematous broad stroma may also be 
present. The edematous stroma is also a microscopic change sometimes observed in pancreatic 
IPMNs.  
iii) In addition to the papillary architecture, tubular components may co-exist, particularly in 
gastric-subtype neoplasms. Tubules are well organized and do not show a cribriform pattern or fused 
glands. Oncocytic-type tumors also show a complex growth pattern (Figure 1C).  
iv) Gross mucin is common (~80%); however, the lack of mucin overproduction does not exclude 
the possibility of type 1 IPNB.  
v) Many cases are composed of high grade dysplasia with not infrequent microscopic foci of 
low/intermediate-grade dysplasia, and actually, some cases are only composed of low/intermediate 
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dysplasia or adenoma, suggesting multi-step carcinogenesis (Figure 1D).  
vi) This subtype is not infrequently associated with invasive carcinomas.  
 
2. Type 2 IPNB (So-called papillary carcinoma or cholangiocarcinoma) 
i) This is also a biliary neoplasm showing predominantly intraductal papillary growth. The papillary 
architecture is complex with thin and occasionally varying thick fibrovascular stalks and often 
associated with irregular branching (Figures 2A and 2B). Tubular, cribriform, and solid components 
may also be observed, but do not exceed 50% of the intraductal components (Figure 2C).  
ii) Tumors show papillary growth with fibrovascular stalks typically >5 mm in the height from the 
adjacent biliary mucosa. This is a useful standard for the discrimination of this neoplasm from 
biliary intraepithelial neoplasia (BilIN), another intraepithelial neoplalsm of bile duct (1), that shows 
micropapillary growth less than 3 mm in height.  
iii) Grossly identifiable mucin overproduction is uncommon (~10%). 
iv) Most cases are histologically the pancreatobiliary or intestinal type, or a mixture of the two. The 
gastric type is rare, while the oncocytic type is exceptional.  
v) Non-invasive components are always high-grade dysplasia with a few identifiable component of 
low/intermediate-grade dysplasia.  
vi) Most cases are associated with invasive growth (Figure 2D), at least focally, at the time of 
surgical resection. Extensive sampling may be required to identify small foci of invasion, 
particularly in tumors with extensive lateral spread. 
 
Unanswered questions to IPNBs to be solved in future 
 Nakanuma -13- 
   This two-nation collaborative meeting by expert pathologists helped us to understand the 
characteristic pathologic features of IPNB and to share the diagnostic pathologic features of IPNB 
and subclassification of IPNB by discussion and reviewing histologically IPNB cases fulfilling the 
proposal of WHO 2010. Although we shared the idea that there are possible two types of IPNBs 
originated by WHO 2010 classification, currently available data are still insufficient for reaching a 
conclusion on how these two IPNBs are related and how these two IPNBs and ordinary bile duct 
cancers are different.  
   Some pathologists insisted that both types share one pathologic condition or stage, “preinvasive 
state”, thus belonging to unique concept of preinvasive intraductal papillary neoplasm of the bile 
duct [1,2], the only difference being that type 1 IPNBs usually arise in the intrahepatic bile ducts and 
type 2 in the extrahepatic bile ducts. Some cases may have overlapping features, thus, may be 
difficult to classify into either of the two types, and some cases present similar IPNBs synchronously 
and/or asynchronously in the intrahepatic as well as extrahepatic bile ducts, supporting the concept 
that type 1 and type 2 IPNBs comprise a spectrum of IPNB along the biliary tree. In addition, type 1 
and type 2 IPNBs are also associated with invasion. In contrast, other investigators insisted that type 
2 IPNB is distinct from type 1 IPNB and more likely to be an extreme papillary variant of 
conventional cholangiocarcinomas, as mentioned below. More clinicopathological studies and 
comparative molecular studies are needed in order to resolve this issue and to clarify the significance 
of this subclassification.  
   Another potential issue relates to differentiation between type 2 IPNB and ordinary bile duct 
cancers. While conventional cholangiocarcinomas typically present nodular/fibrosing growth of the 
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affected bile ducts, they can also contain variable amounts of intraductal growth components with 
tubular or papillotubular adenocarcinoma and fibrous stroma in addition to nodular/sclerosing 
growth of the affected bile ducts, the discrimination between two may not be clear in some cases. 
These facts raise the idea, in which type 2 IPNB is merely a variant of ordinary bile duct cancer. 
Furthermore, since some cases with type 1 and type 2 IPNBs may have overlapping features, as 
mentioned above, there is also an opinion that all types of IPNB may be simply a variant of ordinary 
bile duct cancers. The proposed diagnostic criteria of type 2 IPNB (papillary components comprising 
>50% of the intraductal tumor and papillary growth typically >5 mm in height) will be useful for 
discrimination between IPNB and BilIN. These separation criteria are somewhat arbitrary, but will 
become a reasonable scheme for future investigations. Using the same diagnostic standard is crucial 
for comparing findings among studies toward consensus building on what IPNB is.  
 
Conclusions 
This statement describes that Japan-Korea IPNB expert pathologists reached to the common 
understanding of characteristic and diagnostic pathologic features of IPNBs diagnosed on the basis 
of the WHO 2010 classification and in addition, proposed its possible subclassification into two 
types. Currently, the features of IPNB is still confusing, since there are only data obtained from 
tumors diagnosed as IPNB through the different pathologic criteria. Therefore, the authors hope that 
the proposed diagnostic pathologic features of IPNB and its subtypes stated here will be of use for 
future clinicopathological and molecular analyses. The feedback of the results obtained from these 
future analyses would be expected to lead refinement and optimization of the clinicopathological 
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definition of IPNB.  
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Figure legends 
Figure 1. Histopathological features of classical IPNBs. (A and B) Tumor cells are arranged in an 
overall well-organized, high-papillary architecture. (C) The oncocytic type shows a complex 
architecture with tubular structures. (D) A component of low/intermediate-grade dysplasia may also 
be present.  
 
Figure 2. Histopathological features of type 2 IPNBs/papillary cholangiocarcinomas. (A and B) The 
papillary architecture is complex with irregular branching and thick fibrovascular stalks. (C) Cancer 
cells show a tubular growth with intraluminal necrosis. (D) The tumor is associated with invasive 
cancers.  
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